You are here

Article info

Article menu

Download PDFPDF

XML
Review
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies

Authors

  • Jason D Goldman Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, USA Providence St. Joseph Health, Renton, Washington, USA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Philip C Robinson The University of Queensland Faculty of Medicine, Herston, Queensland, Australia Metro North Hospital and Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia PubMed articlesGoogle scholar articles
  • Thomas S Uldrick Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Per Ljungman Department. of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden Division of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jason D Goldman; jason.goldman{at}swedish.org
View Full Text

Citation

Goldman JD, Robinson PC, Uldrick TS, et al
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Journal for ImmunoTherapy of Cancer 2021;9:e002630. doi: 10.1136/jitc-2021-002630

Publication history

  • Accepted April 27, 2021
  • First published June 11, 2021.
Online issue publication 
February 24, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.